|
May 12, 2022
|
GBT Announces Five Data Presentations on Sickle Cell Disease at Upcoming EHA2022 Congress
|
|
|
May 05, 2022
|
GBT Announces New Employment Inducement Grants
|
|
|
May 05, 2022
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
|
May 04, 2022
|
GBT Reports First Quarter 2022 Financial Results
|
|
|
Apr 28, 2022
|
GBT Launches Inaugural Environmental, Social and Governance (ESG) Report
|
|
|
Apr 27, 2022
|
GBT to Announce First Quarter 2022 Financial Results on Wednesday, May 4, 2022
|
|
|
Apr 07, 2022
|
GBT Announces New Employment Inducement Grants
|
|
|
Mar 24, 2022
|
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day
|
|
|
Mar 10, 2022
|
GBT Announces New Employment Inducement Grants
|
|
|
Mar 03, 2022
|
The GBT Foundation Opens 2022 ACE Grant Program, Providing up to $250,000 in Support to Sickle Cell Disease Community-Based Organizations
|
|
|
Feb 28, 2022
|
GBT Announces Participation in Upcoming Investor Conferences
|
|
|
Feb 23, 2022
|
GBT Reports Fourth Quarter and Full Year 2021 Financial Results
|
|
|
Feb 16, 2022
|
GBT to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday, February 23, 2022
|
|
|
Feb 16, 2022
|
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
|
|
|
Feb 03, 2022
|
GBT Announces New Employment Inducement Grants
|
|
|
Jan 27, 2022
|
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
|
|
|
Jan 10, 2022
|
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
|
|
|
Jan 06, 2022
|
GBT Announces New Employment Inducement Grants
|
|
|
Jan 04, 2022
|
GBT to Present at the 40th Annual J.P. Morgan Healthcare Conference
|
|